$2.48T
Total marketcap
$204.81B
Total volume
BTC 50.08%     ETH 15.66%
Dominance

SpringWorks Therapeutics SWTX Stock

48.43 USD {{ price }} -3.679393% {{change_pct}}%
Exchange
NasdaqGS
Market Cap
3.57B USD
LOW - HIGH [24H]
48.38 - 50.63 USD
VOLUME [24H]
1.12M USD
{{ volume }}
P/E Ratio
0
Earnings per share
-5.15 USD

SpringWorks Therapeutics Price Chart

SpringWorks Therapeutics SWTX Financial and Trading Overview

SpringWorks Therapeutics stock price 48.43 USD
Previous Close 27.56 USD
Open 27.37 USD
Bid 0 USD x 800
Ask 0 USD x 800
Day's Range 27.01 - 28.66 USD
52 Week Range 20.7 - 39.78 USD
Volume 558.86K USD
Avg. Volume 667.57K USD
Market Cap 1.75B USD
Beta (5Y Monthly) 0.568159
PE Ratio (TTM) N/A
EPS (TTM) -5.15 USD
Forward Dividend & Yield N/A (N/A)
Ex-Dividend Date N/A
1y Target Est 55.8 USD

SWTX Valuation Measures

Enterprise Value 1.2B USD
Trailing P/E N/A
Forward P/E -6.6179247
PEG Ratio (5 yr expected) N/A
Price/Sales (ttm) N/A
Price/Book (mrq) 3.4518392
Enterprise Value/Revenue N/A
Enterprise Value/EBITDA -4.046

Trading Information

SpringWorks Therapeutics Stock Price History

Beta (5Y Monthly) 0.568159
52-Week Change 28.47%
S&P500 52-Week Change 20.43%
52 Week High 39.78 USD
52 Week Low 20.7 USD
50-Day Moving Average 26.44 USD
200-Day Moving Average 26.85 USD

SWTX Share Statistics

Avg. Volume (3 month) 667.57K USD
Avg. Daily Volume (10-Days) 753.79K USD
Shares Outstanding 62.52M
Float 39.86M
Short Ratio 18.29
% Held by Insiders 6.51%
% Held by Institutions 106.93%
Shares Short 12.36M
Short % of Float 24.04%
Short % of Shares Outstanding 19.77%

Dividends & Splits

Trailing Annual Dividend Rate 0
Trailing Annual Dividend Yield 0%
5 Year Average Dividend Yield N/A
Payout Ratio 0
Last Split Factor

Financial Highlights

Fiscal Year

Fiscal Year Ends December 31, 2022
Most Recent Quarter (mrq) March 31, 2023
Next Fiscal Year End December 31, 2023

Profitability

Profit Margin 0%
Operating Margin (ttm) 0%
Gross Margin 0%
EBITDA Margin 0%

Management Effectiveness

Return on Assets (ttm) -38.073%
Return on Equity (ttm) -65.41%

Income Statement

Revenue (ttm) N/A
Revenue Per Share (ttm) N/A
Quarterly Revenue Growth (yoy) N/A
Gross Profit (ttm) N/A
EBITDA -295993984 USD
Net Income Avi to Common (ttm) -289036000 USD
Diluted EPS (ttm) -5.17
Quarterly Earnings Growth (yoy) N/A

Balance Sheet

Total Cash (mrq) 528.14M USD
Total Cash Per Share (mrq) 8.47 USD
Total Debt (mrq) 7.05M USD
Total Debt/Equity (mrq) 1.39 USD
Current Ratio (mrq) 14.241
Book Value Per Share (mrq) 8.129

Cash Flow Statement

Operating Cash Flow (ttm) -174692992 USD
Levered Free Cash Flow (ttm) -103555000 USD

Profile of SpringWorks Therapeutics

Country United States
State CT
City Stamford
Address 100 Washington Boulevard
ZIP 06902
Phone 203 883 9490
Website https://www.springworkstx.com
Industry Biotechnology
Sector(s) Healthcare
Full Time Employees 227

SpringWorks Therapeutics, Inc. acquires, develops, and commercializes medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is nirogacestat, an oral small molecule gamma secretase inhibitor that is in Phase III DeFi trial for the treatment of desmoid tumors. The company is also developing mirdametinib, an oral small molecule MEK inhibitor that is in Phase 2b clinical trials for the treatment of neurofibromatosis type 1-associated plexiform neurofibromas, as well as Phase 1/2a clinical trial for the treatment of NF1-PN; mirdametinib + lifirafenib, a combination therapy that is in Phase 1b/2 clinical trial in patients with advanced or refractory solid tumors; and mirdametinib in monotherapy and combination approaches to treat solid tumors. In addition, it develops BGB-3245, an oral selective small molecule inhibitor of monomeric and dimeric forms of activating BRAF mutations. The company has collaborations with BeiGene, Ltd. and GlaxoSmithKline LLC; and license agreements with Pfizer Inc. for nirogacestat and mirdametinib. It also has a license agreement with Katholieke Universiteit Leuven and the Flanders Institute for Biotechnology for a portfolio of novel small molecule inhibitors of the TEA Domain; and Dana-Farber Cancer Institute for a portfolio of novel small molecule inhibitors of Epidermal Growth Factor Receptor. The company was founded in 2017 and is headquartered in Stamford, Connecticut.

Q&A For SpringWorks Therapeutics Stock

What is a current SWTX stock price?

SpringWorks Therapeutics SWTX stock price today per share is 48.43 USD.

How to purchase SpringWorks Therapeutics stock?

You can buy SWTX shares on the NasdaqGS exchange. Contact your financial advisor to select a broker.

What is the ticker symbol for SpringWorks Therapeutics?

The stock symbol or ticker of SpringWorks Therapeutics is SWTX.

Which industry does the SpringWorks Therapeutics company belong to?

The SpringWorks Therapeutics industry is Biotechnology.

How many shares does SpringWorks Therapeutics have in circulation?

The max supply of SpringWorks Therapeutics shares is 73.79M.

What is SpringWorks Therapeutics Price to Earnings Ratio (PE Ratio)?

SpringWorks Therapeutics PE Ratio is now.

What was SpringWorks Therapeutics earnings per share over the trailing 12 months (TTM)?

SpringWorks Therapeutics EPS is -5.15 USD over the trailing 12 months.

Which sector does the SpringWorks Therapeutics company belong to?

The SpringWorks Therapeutics sector is Healthcare.

SpringWorks Therapeutics SWTX included in indexes

Name Name Price Price 24h%
7d chart
24h% & 7d
VOL Volume 24h low 24h high Volume
Name Name Price Price 24h%
7d chart
24h% & 7d
VOL Volume 24h low 24h high Volume
{{ item.name }} {{ item.symbol }} {{ item.price }} {{ item.price_usd }}
{{ item.change_pct }}
{{ item.volume }} {{ item.volume_usd }} {{ item.low }} {{ item.low_usd }} {{ item.high }} {{ item.high_usd }} {{ item.components_count }} {{ item.volume }} {{ item.volume_usd }}
NASDAQ Composite IXIC 16103.45 USD
+0.82
4.52B USD 16094.17 USD 16247.59 USD 4.52B USD
NASDAQ Global Select Market Com NQGS 7837.41 USD
+0.85
7832.7 USD 7908.95 USD
NASDAQ Biotechnology NBI 4337.34 USD
-0.65
4335.84 USD 4376.86 USD
NASDAQ HealthCare IXHC 986.88 USD
-0.25
986.44 USD 994.67 USD
Nasdaq US 700 Small Cap Index NQUS700SC 2078.81 USD
-0.4
2075.76 USD 2093.28 USD
Stlmt ID NASDAQ Biotechnology NBX 4604.4 USD
-2.98
4555.41 USD 4917.8 USD